Anator Use In Pregnancy & Lactation

Women of child-bearing potential should use adequate birth-control measures during treatment with anagrelide.
Pregnancy: There are no adequate data from the use of anagrelide in pregnant women. Studies in animals have shown reproductive toxicity. The potential risk for humans is unknown. Therefore, Anagrelide is not recommended during pregnancy.
If anagrelide is used during pregnancy, or if the patient becomes pregnant while using the medicinal product, she should be advised of the potential risk to the foetus.
Breast-feeding: It is unknown whether anagrelide/metabolites are excreted in human milk. Available data in animals have shown excretion of anagrelide/metabolites in milk. A risk to the newborn/infant cannot be excluded. Breast-feeding should be discontinued during treatment with anagrelide.
Fertility: No human data on the effect of anagrelide on fertility are available. In male rats, there was no effect on fertility or reproductive performance with anagrelide. In female rats, using doses in excess of the therapeutic range, anagrelide disrupted implantation.